K. Parhofer and P. Barrett, Thematic review series: Patient-Oriented Research. What we have learned about VLDL and LDL metabolism from human kinetics studies, The Journal of Lipid Research, vol.47, issue.8, pp.1620-1650, 2006.
DOI : 10.1194/jlr.R600013-JLR200

M. Fernandez, E. Lin, and D. Mcnamara, Differential effects of saturated fatty acids on low density lipoprotein metabolismnea pig, J Lipid research, vol.33, pp.1833-1875, 1992.

D. Steinberg, S. Parthasarathy, T. Carew, J. Khoo, and J. Witztum, Beyond cholesterol. Modifications of lowdensity lipoprotein that increase its atherogenicity, N Engl J Med, vol.320, pp.915-939, 1989.

M. Quinn, S. Parthasarathy, and D. Steinberg, Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein., Proceedings of the National Academy of Sciences, vol.82, issue.17, pp.5949-53, 1985.
DOI : 10.1073/pnas.82.17.5949

R. Stocker, J. Keaney, and J. , Role of Oxidative Modifications in Atherosclerosis, Physiological Reviews, vol.84, issue.4, pp.1381-478, 2004.
DOI : 10.1152/physrev.00047.2003

M. Diaz, B. Frei, J. Vita, J. Keaney, and J. , Antioxidants and atherosclerotic heart disease, N Engl J Med, vol.337, pp.408-424, 1997.

U. Steinbrecher, S. Parthasarathy, D. Leake, J. Witztum, and D. Steinberg, Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids., Proceedings of the National Academy of Sciences, vol.81, issue.12, pp.3883-3890, 1984.
DOI : 10.1073/pnas.81.12.3883

N. Gopaul, E. Anggard, A. Mallet, D. Betteridge, S. Wolff et al., levels are elevated in individuals with non-insulin dependent diabetes mellitus, FEBS Letters, vol.23, issue.2, pp.225-234, 1995.
DOI : 10.1016/0014-5793(95)00649-T

K. Griendling, D. Sorescu, B. Lassegue, and M. Ushio-fukai, Modulation of Protein Kinase Activity and Gene Expression by Reactive Oxygen Species and Their Role in Vascular Physiology and Pathophysiology, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.20, issue.10, pp.2175-83, 2000.
DOI : 10.1161/01.ATV.20.10.2175

K. Griendling and M. Ushio-fukai, Reactive oxygen species as mediators of angiotensin II signaling, Regulatory Peptides, vol.91, issue.1-3, pp.21-28, 2000.
DOI : 10.1016/S0167-0115(00)00136-1

J. Morrow, B. Frei, and A. Longmire, -Isoprostanes) in Smokers ??? Smoking as a Cause of Oxidative Damage, New England Journal of Medicine, vol.332, issue.18, pp.1198-203, 1995.
DOI : 10.1056/NEJM199505043321804

URL : https://hal.archives-ouvertes.fr/in2p3-00024374

C. Nathan, Points of control in inflammation, Nature, vol.17, issue.6917, pp.846-52, 2002.
DOI : 10.1073/pnas.94.20.10919

N. Stone, J. Robinson, and A. Lichtenstein, AHA guideline on the treatment of blood cholesterol to reduce atherosclerosic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, ACC Circulation, vol.10, pp.1161-1201, 2013.

A. Endo, The discovery and development of HMG-CoA reductase inhibitors, Atherosclerosis Supplements, vol.5, issue.3, pp.1569-82, 1992.
DOI : 10.1016/j.atherosclerosissup.2004.08.026

S. M. Grundy, HMG-CoA reductase inhibitors for treatment of hypercholesterolemia, N. Engl. J. Med, vol.319, pp.24-33, 1988.

C. Treatment-trialists-'(-ctt-)-collaboration, C. Balgent, L. Blackwell, and J. Emberson, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170???000 participants in 26 randomised trials, The Lancet, vol.376, issue.9753, pp.1670-81, 2010.
DOI : 10.1016/S0140-6736(10)61350-5

S. Navaneethan, F. Pansini, and V. Perkovic, HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis, Cochrane Database Syst Rev, vol.336, issue.7645, p.7784, 2009.
DOI : 10.1002/14651858.CD007784

J. Liao, Clinical implications for statin pleiotropy, Current Opinion in Lipidology, vol.16, issue.6, pp.624-633, 2005.
DOI : 10.1097/01.mol.0000191913.16321.60

B. Verges, Les effets pléiotropes des statines ont-ils un interêt clinique ? Arch Mal Coeur Vaiss, pp.1231-1236, 2004.

P. Thompson, P. Clarkson, and R. Rosenson, An Assessment of Statin Safety by Muscle Experts, The American Journal of Cardiology, vol.97, issue.8, pp.69-76, 2006.
DOI : 10.1016/j.amjcard.2005.12.013

J. Armitage, The safety of statins in clinical practice, The Lancet, vol.370, issue.9601, pp.1781-1790, 2007.
DOI : 10.1016/S0140-6736(07)60716-8

N. Sattar, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, The Lancet, vol.375, issue.9716, pp.735-777, 2010.
DOI : 10.1016/S0140-6736(09)61965-6

N. Swapnil and . Rajpathak, Statin therapy and risk of Developing Type 2 diabete: A meta-Analysis, Diabetes Care, vol.32, issue.10, pp.1924-1953, 2009.

H. Inhibitors, atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, pitavastatin, rosuvastatin) and safety the risk of nowonset diabetes/impaired glucose metabolism Agreed by PhVWP, Heads of Medicines Agencies. Mars, 2012.

J. Shepherd, G. Blauw, and M. Murphy, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, The Lancet, vol.360, issue.9346, pp.1623-1632, 2002.
DOI : 10.1016/S0140-6736(02)11600-X

. Ridker, Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein, New England Journal of Medicine, vol.359, issue.21, pp.2195-207, 2008.
DOI : 10.1056/NEJMoa0807646

J. Afilalo and G. Duque, Statins for Secondary Prevention in Elderly Patients, Journal of the American College of Cardiology, vol.51, issue.1, pp.37-45, 2008.
DOI : 10.1016/j.jacc.2007.06.063

I. Schatz, Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study, The Lancet, vol.358, issue.9279, pp.351-356, 2001.
DOI : 10.1016/S0140-6736(01)05553-2

G. Wannamethee, A. Shaper, P. Whincup, and M. Walker, Low serum total cholesterol concentrations and mortality in middle aged British men, BMJ, vol.311, issue.7002, pp.409-422, 1995.
DOI : 10.1136/bmj.311.7002.409

B. Psaty and C. Furberg, Traditional Risk Factors and Subclinical Disease Measures as Predictors of First Myocardial Infarction in Older Adults, Archives of Internal Medicine, vol.159, issue.12, pp.1339-1386, 1999.
DOI : 10.1001/archinte.159.12.1339

J. Emmerich, E. Bruckert, and F. Delahaye, Relations between HDL-cholestérol and cardiovascular disease, Arch Mal Coeur Vaiss, vol.85, issue.3, pp.21-28, 1992.

W. Kannel, M. Feinleib, P. Mcnamara, R. Garrisson, and W. Castelli, AN INVESTIGATION OF CORONARY HEART DISEASE IN FAMILIES, American Journal of Epidemiology, vol.110, issue.3, pp.281-90, 1979.
DOI : 10.1093/oxfordjournals.aje.a112813

J. Neaton and D. Wentworth, Serum Cholesterol, Blood Pressure, Cigarette Smoking, and Death From Coronary Heart Disease Overall Findings and Differences by Age for 316099 White Men, Archives of Internal Medicine, vol.152, issue.1, pp.56-64, 1992.
DOI : 10.1001/archinte.1992.00400130082009

A. Weverling-rijnsburger, G. Blauw, and A. Lagaay, Total cholesterol and risk of mortality in the oldest old, The Lancet, vol.350, issue.9085, pp.1119-1142, 1997.
DOI : 10.1016/S0140-6736(97)04430-9

B. Forette, D. Tortrat, and Y. Wolmark, CHOLESTEROL AS RISK FACTOR FOR MORTALITY IN ELDERLY WOMEN, The Lancet, vol.333, issue.8643, pp.868-70, 1989.
DOI : 10.1016/S0140-6736(89)92865-1

M. Law, N. Wald, and S. Thompson, By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?, BMJ, vol.308, issue.6925, pp.367-72, 1994.
DOI : 10.1136/bmj.308.6925.367

S. Gover and S. Paquet, Estimating the Benefits of Modifying Risk Factors of Cardiovascular Disease, Archives of Internal Medicine, vol.158, issue.6, pp.655-62, 1998.
DOI : 10.1001/archinte.158.6.655

M. De-lorgeril, P. Salen, I. Monjaud, and J. Delaye, The 'diet heart' hypothesis in secondary prevention of coronary heart disease, European Heart Journal, vol.18, issue.1, pp.13-21, 1997.
DOI : 10.1093/oxfordjournals.eurheartj.a015094

URL : https://hal.archives-ouvertes.fr/hal-00395471

A. Trichopoulou and C. Bamia, Anatomy of health effects of Mediterranean diet: Greek EPIC prospective cohort study, BMJ, vol.338, issue.jun23 2, pp.2337-2338, 2009.
DOI : 10.1136/bmj.b2337

L. Mackinnon and L. Hubinger, Effects of Exercise on Lipoprotein(a), Sports Medicine, vol.28, issue.1, pp.11-24, 1999.
DOI : 10.2165/00007256-199928010-00002

H. Blain, A. Vuillemin, A. Blain, and C. Jeandel, Médecine préventive chez les personnes agées: les effets préventifs de l'ativité physique chez les personnes agées, Presse Med, vol.29, pp.1240-1248, 2000.

A. Gulsvik, D. Thelle, and S. Samuelsen, Ageing, physical activity and mortality--a 42-year follow-up study, International Journal of Epidemiology, vol.41, issue.2
DOI : 10.1093/ije/dyr205